Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplantation (Memorial University of Newfoundland)
- Development stage
- Unknown
- Lead developer
- Memorial University of Newfoundland
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This investigational fecal microbiota transplantation (FMT) product, developed by the Memorial University of Newfoundland, is an oral, encapsulated formulation of live commensal bacteria derived from healthy donor stool. Unlike traditional FMT, which is typically reserved for recurrent *Clostridium difficile* infections and administered via invasive routes, this specific product is being evaluated in Phase 3 clinical trials as a primary (first-line) therapy for *Clostridium difficile*-associated diarrhea (CDAD). The treatment aims to rapidly restore the diversity and functional integrity of the gut microbiome, which is often depleted by antibiotic use. By reintroducing a complex microbial ecosystem, the therapy provides colonization resistance against *C. difficile* through nutrient competition, niche exclusion, and the restoration of secondary bile acid metabolism, which inhibits the germination and vegetative growth of the pathogen.
- Other names
- Oral encapsulated FMTFMT capsulesFecal microbiota transplantation capsules
Beyond the preview
Go deeper on Fecal microbiota transplantation (Memorial University of Newfoundland).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fecal microbiota transplantation (Memorial University of Newfoundland).